Scancell Holdings plc (AIM: SCLP), a developer of novel immunotherapy products to treat cancer, announced on Wednesday that it has commenced dosing in Cohort 4 of its Phase 2 SCOPE study, evaluating intradermal administration and an accelerated dosing schedule of iSCIB1+ Immunobody immunotherapy in patients with advanced unresectable melanoma.

The first eight patients, including those recruited through the NHS Cancer Vaccine Launch Pad, have been safely dosed with no significant adverse events observed. Interim data from this cohort are expected around the end of 2025, while results from Cohorts 1–3 remain on track for release in July 2025.

Cohort 4 focuses on delivering iSCIB1+ intradermally, aiming to enhance immune response. Cohort 3, now fully enrolled, evaluated iSCIB1+ with checkpoint inhibitors ipilimumab and nivolumab. Earlier data from Cohort 1 showed an 84% disease control rate, 80% progression-free survival, 20% complete response rate, and 72% overall response rate.

The SCOPE trial (NCT04079166) will enrol over 140 patients to assess the efficacy and safety of SCIB1 and iSCIB1+ in combination with standard checkpoint inhibitors. Scancell's iSCIB1+ was developed using its AvidiMab platform to boost potency and broaden patient applicability through additional melanoma-specific epitopes.